Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma, Renal Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Angiogenesis Inhibitors

Sunitinib

ASL MRI performed at different time intervals on participants receiving sunitnib or pazopanib for treating RCC

ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC

Arterial Spin Labeling Magnetic Resonance Imaging

Leo Tsai, MD

The purpose of this study is to assess magnetic resonance imaging (MRI) as a tool to track tumor growth for renal cell carcinoma while the participant is receiving clinical treatment therapy with sunitinib or pazopanib. An MRI is a sophisticated type of scan that uses powerful magnets to make clearer images or to focus on detailed medical information in the participants abdomen and pelvis. This imaging done for this study will use the ASL MRI technique that allows us to see blood flow changes which possibly may indicated tumor growth.

* MRI's will be performed at specific time points during the participants treatment for renal cell carcinoma with the drug sunitinib or pazopanib. These ASL MRI's will be performed at baseline, 2 weeks upon initiation of therapy with sunitinib/pazopanib, after cycle 2 and/or cycle 4 of therapy, and at the end of therapy.
* The MRI tests for all participants will be done at Beth Israel Deaconess Medical Center.

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Antiangiogenic and Targeted Therapies of Metastatic Renal Cell Carcinoma

Dana-Farber Cancer Institute

Brigham and Women's Hospital

Pfizer

Novartis

Beth Israel Deaconess Medical Center

Principal Investigator

Patients undergo DCE, DSC, or ASL pMRI within 30 days of biopsy or surgery. Patients with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI at 1-6 months.

Undergo arterial spin labeled perfusion magnetic resonance imaging

Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging

Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging

Undergo perfusion magnetic resonance imaging

Perfusion Magnetic Resonance Imaging

David Foran

This pilot clinical trial studies perfusion magnetic resonance imaging in diagnosing patients with kidney tumors. Diagnostic procedures, such as perfusion magnetic resonance imaging, may help find and diagnose kidney tumors and predict and monitor a patient's response to treatment.

PRIMARY OBJECTIVES:

I. To investigate the utility of perfusion magnetic resonance imaging (pMRI) as a diagnostic biomarker for the prediction of malignant vs. benign organ confined renal masses.

II. To investigate the utility of pMRI as a therapeutic biomarker for monitoring tumor progression in patients undergoing treatment (ablation, surgery, specific systemic treatments such as interleukin 2 (IL-2) or vascular endothelial growth factor \[VEGF\]/vascular endothelial growth factor receptor \[VEGFR\]/mechanistic target of rapamycin \[mTOR\] targeted therapies) or active surveillance for organ confined or metastatic renal tumors.

SECONDARY OBJECTIVES:

I. To investigate the utility of pMRI to predict tumor grade and histologic subtype of organ confined kidney cancers.

OUTLINE:

Patients undergo dynamic contrast enhanced (DCE), dynamic susceptibility contrast (DSC), or arterial spin labeled (ASL) pMRI within 30 days of biopsy or surgery. Patients with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI at 1-6 months.

After completion of study, patients are followed up within 48 hours.

Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors

Pilot Study of Renal Neoplasms With Perfusion Magnetic Resonance Imaging

Univariate and multivariate analyses will be performed to look for associations between pMRI outputs and tumor histopathology. The utilization of perfusion MRI as a diagnostic biomarker for tumor grade and histological subtype will be assessed by correlative comparison to histological evaluation by pathology.

Kaplan-Meier survival curves will be performed to compare groups of patients to assess progression-free survival.

If possible, receiver operating characteristic curves will be created from pMRI data.

The utility of pMRI as a therapeutic biomarker for monitoring or predicting treatment response will be assessed by correlative comparison to progression free survival and/or radiographic tumor evaluation by standard of care radiologic imaging modality, such as Response Evaluation Criteria in Solid Tumors.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)	NCT00749320	Renal Cell Carc...	Arterial Spin L...	18 Years -	Dana-Farber Cancer Institute
Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors	NCT02526511	Stage I Renal C... Stage II Renal ... Stage III Renal... Stage IV Renal ...	Arterial Spin L... Dynamic Contras... Dynamic Suscept... Perfusion Magne...	18 Years -	Rutgers, The State University of New Jersey
Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors	NCT02526511	Stage I Renal C... Stage II Renal ... Stage III Renal... Stage IV Renal ...	Arterial Spin L... Dynamic Contras... Dynamic Suscept... Perfusion Magne...	18 Years -	Rutgers, The State University of New Jersey

Spots Global Cancer Trial Database for arterial spin labeling magnetic resonance imaging